Ahmedabad: Torrent Pharmaceuticals Limited (‘’Company”) today announced its financial results for the third quarter of FY 26.
Key Highlights for Q3 FY26:
- Revenue at Rs. 3,303 crores, up by 18% YoY
- Op. EBITDA* at Rs.1,088 crores, up by 19% YoY
- Op. EBITDA margin* at 33%; Gross Margin: 76%
- Net Profit after tax at Rs. 635 crores, up by 26% YoY
Performance summary:
| Results | Q3 FY26 | Q3 FY25 | YoY % |
9M FY26 | 9M FY25 | YoY % |
||||
| Rs cr | % | Rs cr | % | Rs cr | % | Rs cr | % | |||
| Revenues | 3,303 | 2,809 | 18% | 9,783 | 8,557 | 14% | ||||
| Gross profit | 2,504 | 76% | 2,136 | 76% | 17% | 7,410 | 76% | 6,512 | 76% | 14% |
| Op EBITDA* | 1,088 | 33% | 914 | 33% | 19% | 3,203 | 33% | 2,757 | 32% | 16% |
| Exceptional item** | (10) | 0% | – | – | – | (23) | 0% | – | – | – |
| PAT | 635 | 19% | 503 | 18% | 26% | 1,774 | 18% | 1,413 | 17% | 26% |
| R&D spend | 154 | 5% | 151 | 5% | 2% | 468 | 5% | 431 | 5% | 9% |
*Before exceptional items
** Exceptional item comprises regulatory & statutory filing fees and other related costs associated with acquisition of J.B. Chemicals & Pharmaceuticals Ltd.
India:
- India revenues at Rs 1,798 crores were up 14%
- As per AIOCD PharmaTrac secondary market data, IPM growth for the quarter was 10%.
- Continued volume outperformance over IPM in chronic and sub-chronic therapies led by Cardiac, Gastro, and Diabetes (OAD) segments
- For 9M FY26, revenues were Rs 5,430 crores, up by 12%.
Brazil:
- Brazil revenues at Rs 371 crores, were up by 27%.
- Constant currency revenues, at R$ 224 million, were up by 10%.
- As per IQVIA, Torrent grew at 13% vs market growth of 7%; growth was aided by the performance of top brands & recent launches.
- Torrent has 60 products under ANVISA review.
- For 9M FY26, revenues were Rs 907 crores, up by 21% (Constant currency revenue: R$ 564 million, up by 13%).
United States:
- US business revenues at Rs 321 crores, were up by 19%.
- Constant currency revenues at $36 million, were up by 12% compared to the same period in the previous year. Recent launches have achieved target market shares.
- For 9M FY26, revenues were Rs 967 crores, up by 21% (Constant currency revenue: $111 million up by 16%).
Germany:
- Germany revenues at Rs 304 crores, were up by 8%.
- Constant currency revenues at EUR 29 million, were down by 6%.
- Growth continued to be impacted due to supply disruption at a third party supplier.
- For 9M FY26, revenues were Rs 916 crores, up by 7% (Constant currency revenue: EUR 91 million, down by 3%).
